Jane Street’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-14,668
| Closed | -$32.4K | – | 9669 |
|
|
2023
Q2 | $32.4K | Sell |
14,668
-24,850
| -63% | -$51.5K | ﹤0.01% | 8296 |
|
|
2023
Q1 | $100K | Buy |
39,518
+22,633
| +134% | +$44.7K | ﹤0.01% | 8227 |
|
|
2022
Q4 | $31.6K | Buy |
16,885
+2,865
| +20% | +$7.14K | ﹤0.01% | 8491 |
|
|
2022
Q3 | $36K | Buy |
+14,020
| New | +$34.9K | ﹤0.01% | 9046 |
|
|
2021
Q4 | – | Sell |
-24,392
| Closed | -$119K | – | 11029 |
|
|
2021
Q3 | $119K | Sell |
24,392
-5,126
| -17% | -$28.2K | ﹤0.01% | 9200 |
|
|
2021
Q2 | $201K | Buy |
29,518
+12,863
| +77% | +$104K | ﹤0.01% | 8820 |
|
|
2021
Q1 | $118K | Sell |
16,655
-255
| -2% | -$1.84K | ﹤0.01% | 8574 |
|
|
2020
Q4 | $106K | Buy |
+16,910
| New | +$99.5K | ﹤0.01% | 7191 |
|
|
2020
Q3 | – | Sell |
-33,039
| Closed | -$164K | – | 8168 |
|
|
2020
Q2 | $172K | Buy |
+33,039
| New | +$147K | ﹤0.01% | 6462 |
|
|
2014
Q4 | – | Sell |
-5,166
| Closed | -$126K | – | 3162 |
|
|
2014
Q3 | $126K | Buy |
5,166
+4,164
| +416% | +$109K | ﹤0.01% | 2330 |
|
|
2014
Q2 | $24K | Buy |
+1,002
| New | +$32.7K | ﹤0.01% | 2467 |
|
|
2013
Q4 | – | Sell |
-839
| Closed | -$32K | – | 3012 |
|
|
2013
Q3 | $32K | Sell |
839
-167
| -17% | -$5.98K | ﹤0.01% | 2625 |
|
|
2013
Q2 | $36K | Buy |
+1,006
| New | +$43.1K | ﹤0.01% | 2567 |
|
Jane Street's PRTK Position: Q3 2023 in Review
Jane Street sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2023, closing a stake of 14,668 shares — an estimated $32.4K sold.
Jane Street first reported a position in PRTK in Q2 2013 and held it in 13 quarters. The position peaked at $201K in Q2 2021. 0 funds tracked by Wall St. Rank hold PRTK as of Q3 2023.
- Jane Street reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- Jane Street sold 14,668 Paratek Pharmaceuticals, Inc. shares in Q3 2023, an estimated $32.4K.
- Jane Street first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2013 and held it in 13 quarters.
- Jane Street's Paratek Pharmaceuticals, Inc. position peaked at $201K in Q2 2021.
- 0 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2023.
Based on Jane Street's 13F filing for Q3 2023, filed 15 Nov 2023.